CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, announced that the Company will release its third quarter 2015 financial results after market close on Tuesday, November 10, 2015.
Management will conduct a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live over the Internet and can be accessed by logging on to the "Investors & Media" section of the Dicerna Pharmaceuticals website, www.dicerna.com, prior to the event. The webcast will also be archived on the Company's website.
The call can also be accessed by dialing (855)-453-3834 or (484) 756-4306 (international), and referencing conference ID 60966533 prior to the start of the call. After the conference call, a replay will be available until November 16, 2015. To access the replay, please dial 855-859-2056 or 404-537-3406, and refer to conference ID 60966533.
About Dicerna Pharmaceuticals
Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.